|Application:||Gene expression microarray analysis|
|Number of samples:||140|
|Release date:||Nov 28 2017|
|Last update date:||Aug 13 2018|
|Diseases:||Leukemia, T-Cell, Leukemia, Prolymphocytic, T-Cell|
|Dataset link||The molecular basis of T-PLL is an actionable perturbation of TCL1/ATM- and epigenetically instructed damage responses [human gene expression array]|
Purified T-cells from 98 T-PLL patients (Supplementary Data1 for additional information) were analyzed using various high-throughput profiling platforms (overlap indicated): Illumina HumanHT‑12 v4 BeadChip arrays (n=70 cases) for gene expression profiling (GEP). CD3+ pan T-cells isolated from peripheral blood (PB) of healthy donors with a similar age-median were used as “normal” controls for GEP (n=10). The isolation strategy of PB tumor cells and matched same-sample germline controls from PB mononuclear cells (PBMCs) of T-PLL patients employed a two-step magnetic separation (MACS columns) process: (1) Positive enrichment of T-PLL tumor cells: magnetic beads bound to anti-CD4 or anti-CD8 antibodies (Microbeads, Miltenyi Biotec) and LS Columns (Miltenyi Biotec) were used. The specificity of beads was selected according to the individual immunophenotype. (2) Depletion of residual T-PLL cells from the flow-through designated as normal control: Depletion Columns (LD, Miltenyi Biotec) were used to remove residual CD4 or CD8 positive cells from the flow-through obtained from step 1. For further details, see Methods section.
Citations per year